Literature DB >> 19762535

Distinct expression patterns of CD123 and CD34 on normal bone marrow B-cell precursors ("hematogones") and B lymphoblastic leukemia blasts.

Nagwa M Hassanein1, Felisa Alcancia, Kathryn R Perkinson, Patrick J Buckley, Anand S Lagoo.   

Abstract

We compared the expression of CD123, the alpha chain of the interleukin-3 receptor, on normal B-cell precursors in bone marrow ("hematogones") from 75 specimens and on leukemic blasts in 45 newly diagnosed B-acute lymphoblastic leukemias (B-ALL) cases. We found that the less mature hematogones (dim CD45+) that express CD34 lack CD123 expression, whereas the more mature hematogones (moderate CD45+) lack CD34 but always express CD123. In contrast with this discordant pattern of CD34 and CD123 expression in hematogones, blasts in 41 (91%) of 45 cases of B-ALL showed concordant expression of the 2 antigens: 80% (36 of 45) cases expressed both antigens, whereas 11% (5 of 45) expressed neither. We found that these distinct patterns of CD34/CD123 expression on hematogones (discordant) and B-ALL blasts (concordant) remain stable after chemotherapy and are useful in differentiating small populations of residual blasts from hematogones that may be simultaneously present.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19762535     DOI: 10.1309/AJCPO4DS0GTLSOEI

Source DB:  PubMed          Journal:  Am J Clin Pathol        ISSN: 0002-9173            Impact factor:   2.493


  16 in total

1.  BCR-ABL1 and CD66c exhibit high concordance in minimal residual disease detection of adult B-acute lymphoblastic leukemia.

Authors:  Gu-Sheng Tang; Jun Wu; Min Liu; Hui Chen; Shen-Glan Gong; Jian-Min Yang; Xiao-Xia Hu; Jian-Min Wang
Journal:  Am J Transl Res       Date:  2015-03-15       Impact factor: 4.060

2.  Development of acute lympboblastic leukemia in a patient with increased hematogones after toxic bone marrow damage.

Authors:  Stefan Gattenlöhner; Hermann Einsele
Journal:  Int J Clin Exp Pathol       Date:  2010-01-30

Review 3.  [Normal bone marrow and common reactive alterations].

Authors:  A Tzankov; S Dirnhofer; C Beham-Schmid
Journal:  Pathologe       Date:  2012-11       Impact factor: 1.011

4.  Targeted diphtheria toxin to treat BPDCN.

Authors:  David J FitzGerald
Journal:  Blood       Date:  2014-07-17       Impact factor: 22.113

5.  Overcoming the Immunosuppressive Tumor Microenvironment of Hodgkin Lymphoma Using Chimeric Antigen Receptor T Cells.

Authors:  Marco Ruella; Michael Klichinsky; Saad S Kenderian; Olga Shestova; Amy Ziober; Daniel O Kraft; Michael Feldman; Mariusz A Wasik; Carl H June; Saar Gill
Journal:  Cancer Discov       Date:  2017-06-02       Impact factor: 39.397

6.  Rapid Turnover and High Production Rate of Myeloid Cells in Adult Rhesus Macaques with Compensations during Aging.

Authors:  Ziyuan He; Carolina Allers; Chie Sugimoto; Nursarat Ahmed; Hideki Fujioka; Woong-Ki Kim; Elizabeth S Didier; Marcelo J Kuroda
Journal:  J Immunol       Date:  2018-05-04       Impact factor: 5.422

7.  Dual CD19 and CD123 targeting prevents antigen-loss relapses after CD19-directed immunotherapies.

Authors:  Marco Ruella; David M Barrett; Saad S Kenderian; Olga Shestova; Ted J Hofmann; Jessica Perazzelli; Michael Klichinsky; Vania Aikawa; Farzana Nazimuddin; Miroslaw Kozlowski; John Scholler; Simon F Lacey; Jan J Melenhorst; Jennifer J D Morrissette; David A Christian; Christopher A Hunter; Michael Kalos; David L Porter; Carl H June; Stephan A Grupp; Saar Gill
Journal:  J Clin Invest       Date:  2016-08-29       Impact factor: 14.808

8.  Targeting Two Antigens Associated with B-ALL with CD19-CD123 Compound Car T Cell Therapy.

Authors:  Lulu E Yan; Hongyu Zhang; Masayuki Wada; Liu Fang; Jia Feng; Wenli Zhang; Qi Chen; Yuanzhen Cao; Kevin G Pinz; Kevin H Chen; Jessica C Petrov; Xi Chen; Lai-Han Leung; Xing-Xing Fan; Lisa Senzel; Xun Jiang; Yupo Ma; William Tse
Journal:  Stem Cell Rev Rep       Date:  2020-04       Impact factor: 5.739

9.  Targeting of acute myeloid leukemia in vitro and in vivo with an anti-CD123 mAb engineered for optimal ADCC.

Authors:  S J Busfield; M Biondo; M Wong; H S Ramshaw; E M Lee; S Ghosh; H Braley; C Panousis; A W Roberts; S Z He; D Thomas; L Fabri; G Vairo; R B Lock; A F Lopez; A D Nash
Journal:  Leukemia       Date:  2014-04-07       Impact factor: 11.528

10.  CD 123 is a membrane biomarker and a therapeutic target in hematologic malignancies.

Authors:  Ugo Testa; Elvira Pelosi; Arthur Frankel
Journal:  Biomark Res       Date:  2014-02-10
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.